Today's Hours: 10:00am - 6:00pm
Lane Medical Library

Search

Filter Results

Did You Mean:

Search Results

Sort by
relevance
  • Book
    edited by Kenneth D. Tew, Francesco Galli.
    Contents:
    1. The epidemiology of selenium and human cancer
    2. Selenoproteins in tumorigenesis and cancer progression
    3. Selenoproteins and metastasis
    4. Selenium-dependent glutathione peroxidases during tumor development
    5. Targeting the selenoprotein thioredoxin reductase 1 for anticancer therapy
    6. The regulation of pathways of inflammation and resolution in immune cells and cancer stem cells by selenium
    7. Selenium and breast cancer risk: focus on cellular and molecular mechanisms
    8. Selenium and epigenetics in cancer: focus on DNA methylation
    9. Selenium and cancer stem cells
    10. Selenocompounds in cancer therapy: an overview.
    Digital Access ScienceDirect 2017
  • Book
    pod redakcją Ryszarda Ergetowskiego.
    Print 1988
  • Article
    Gugler R, Schell A, Eichelbaum M, Fröscher W, Schulz HU.
    Eur J Clin Pharmacol. 1977 Oct 14;12(2):125-32.
    The pharmacokinetics of valproic acid (VPA) have been studied in 6 healthy subjects following a single 600 mg dose, and after multiple doses over 12 days (1200 mg daily) of enteric-coated sodium valproate. A time lag before absorption of 1 to 2 h was observed in each subject, and then absorption was rapid, peak concentrations being recorded 3 to 4 h after administration of the dose. The plasma level decline was biphasic with a terminal half-life of 15.9 +/- 2.6 h in the single dose and 17.3 +/- 3.0 h in the multiple dose experiments. There was no evidence of dose dependent kinetics or autoinduction. Total plasma clearance was 0.0064 +/- 0.0011 l/kg X h. The apparent volume of distribution was small at 0.15 +/- 0.2 l/kg. The mean steady state plasma concentration (Css) reached after 4 days was 81.3 +/- 13.0 microgram/ml. Css observed was lower than Css predicted (99.2 +/- 14.7 microgram/ml) from single dose kinetics (p less than 0.001). The difference was probably due to a reduction in plasma protein binding at higher concentrations. VPA concentration in saliva was between 0.4 and 4.5% of the total plasma concentration and was not equal to the concentration of unbound drug in plasma (6.7 +/- 0.8% unbound). 3.2% of the dose was excreted in urine as the parent drug and 21.2% as conjugated metabolites.
    Digital Access Access Options